Literature DB >> 9029071

Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa positron emission tomography study.

P Piccini1, P K Morrish, N Turjanski, G V Sawle, D J Burn, R A Weeks, M H Mark, D M Maraganore, A J Lees, D J Brooks.   

Abstract

There is increasing evidence for familial aggregation in Parkinson's disease (PD). It is possible that some asymptomatic relatives of PD patients have subclinical nigral Lewy body pathology and their identification could help determine the true prevalence of the disease. We used 18F-dopa positron emission tomography to investigate nigrostriatal dopaminergic terminal function in asymptomatic members of 7 unrelated kindreds in which at least 2 members had parkinsonism. Eight (25%) of the 32 asymptomatic relatives showed abnormal putamen 18F-dopa uptake (2.5 standard deviations below the normal mean). When discriminant function analysis was applied, all of these 8 subjects plus another 3 were classified with high probability as having PD. On neurological examination, 5 of the 32 relatives scanned had an isolated mild postural tremor and 2 of these 5 had reduced putamen uptake. Our findings provide further support for a role of inheritance in the etiology of PD and suggest that the penetrance for nigrostriatal dopaminergic dysfunction in familial clusters of PD is higher than the prevalence of clinical parkinsonism reported in epidemiological surveys.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9029071     DOI: 10.1002/ana.410410213

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  14 in total

1.  Neuropsychological abnormalities in first degree relatives of patients with familial Parkinson's disease.

Authors:  K Dujardin; A Duhamel; E Becquet; C Grunberg; L Defebvre; A Destee
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  Premotor Parkinson's disease: concepts and definitions.

Authors:  Andrew Siderowf; Anthony E Lang
Journal:  Mov Disord       Date:  2012-04-15       Impact factor: 10.338

Review 3.  Positron emission tomography and single-photon emission computed tomography in central nervous system drug development.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2005-04

Review 4.  Neuroimaging in Parkinson's disease.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2004-04

5.  Dopaminergic function in a family with the PARK6 form of autosomal recessive Parkinson's syndrome.

Authors:  K R Kessler; N Hamscho; B Morales; C Menzel; F Barrero; F Vives; S Gispert; G Auburger
Journal:  J Neural Transm (Vienna)       Date:  2005-03-23       Impact factor: 3.575

6.  Positron emission tomography neuroimaging in Parkinson's disease.

Authors:  Clare Loane; Marios Politis
Journal:  Am J Transl Res       Date:  2011-07-10       Impact factor: 4.060

7.  Genome-wide association study confirms extant PD risk loci among the Dutch.

Authors:  Javier Simón-Sánchez; Jacobus J van Hilten; Bart van de Warrenburg; Bart Post; Henk W Berendse; Sampath Arepalli; Dena G Hernandez; Rob M A de Bie; Daan Velseboer; Hans Scheffer; Bas Bloem; Karin D van Dijk; Fernando Rivadeneira; Albert Hofman; André G Uitterlinden; Patrizia Rizzu; Zoltan Bochdanovits; Andrew B Singleton; Peter Heutink
Journal:  Eur J Hum Genet       Date:  2011-01-19       Impact factor: 4.246

8.  Reduced uptake of [¹⁸F]FDOPA PET in asymptomatic welders with occupational manganese exposure.

Authors:  S R Criswell; J S Perlmutter; T O Videen; S M Moerlein; H P Flores; A M Birke; B A Racette
Journal:  Neurology       Date:  2011-04-06       Impact factor: 9.910

9.  Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations.

Authors:  Nathan Pankratz; William C Nichols; Sean K Uniacke; Cheryl Halter; Alice Rudolph; Cliff Shults; P Michael Conneally; Tatiana Foroud
Journal:  Am J Hum Genet       Date:  2002-06-07       Impact factor: 11.025

10.  Prodromal non-motor symptoms of Parkinson's disease.

Authors:  Clelia Pellicano; Dario Benincasa; Vincenzo Pisani; Francesca R Buttarelli; Morena Giovannelli; Francesco E Pontieri
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.